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Abstract: The importance of the gut microbiota in human health is currently well established. It
contributes to many vital functions such as development of the host immune system, digestion
and metabolism, barrier against pathogens or brain–gut communication. Microbial colonization
occurs during infancy in parallel with maturation of the host immune system; therefore, an adequate
cross-talk between these processes is essential to generating tolerance to gut microbiota early in life,
which is crucial to prevent allergic and immune-mediated diseases. Inflammatory bowel disease
(IBD) is characterized by an exacerbated immune reaction against intestinal microbiota. Changes in
abundance in the gut of certain microorganisms such as bacteria, fungi, viruses, and archaea have
been associated with IBD. Microbes that are commonly found in high abundance in healthy gut
microbiomes, such as F. prausnitzii or R. hominis, are reduced in IBD patients. E. coli, which is usually
present in a healthy gut in very low concentrations, is increased in the gut of IBD patients. Microbial
taxa influence the immune system, hence affecting the inflammatory status of the host. This review
examines the IBD microbiome profile and presents IBD as a model of dysbiosis.
Keywords: immune system; dysbiosis; inflammatory bowel disease; Crohn’s disease; ulcerative
colitis; microbiota
1. Introduction
Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders that are not
curable at present. The two main types of IBD are ulcerative colitis (UC) and Crohn’s
disease (CD). UC only manifests in the colon as a continuum inflammation that generally
starts in the distal colon, going forward through the proximal colon until the cecum, and
can lead to ulcerations and bleeding. On the other hand, CD can appear as patched lesions
in any part of the gastrointestinal tract, associated with inflammation, stenosis, and/or
fistulas. These diseases are characterized by a relapsing behavior, manifested by alternating
phases of inactive states in which there is no intestinal inflammation (called remission or
quiescence), and active states that present inflammation or any other disease symptoms
(an active disease) [1]. In addition, IBD patients often receive multiple treatments and the
response to treatment is highly variable depending on the subject, demonstrating the need
for a deeper understanding of the disease as well as innovative therapeutics approaches.
Growing insights into immunomediated diseases pathophysiology, such as IBD, have led
to the advent of targeted therapies, which could selectively interfere with crucial mediators
of the inflammatory process [2–5].
IBD is a multifactorial disease with an unknown etiology. IBD presents defects in the
detection and control of the gut microbiota, associated with unbalanced immune reactions,
genetic mutations that confer susceptibility to the disease, and complex environmental
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conditions such as westernized lifestyle [6,7]. Moreover, IBD susceptibility is associated
with polymorphisms in host microbial sensory genes such as NOD2 and Toll-like receptor
(TLR) 4 [8]. Therefore, currently the most accepted etiopathogenic theory is that IBD
is caused by an impairment in the immunological tolerance, resulting in an exacerbated
immune reaction against the gut microbiota in genetic-susceptible individuals. Nonetheless,
whether the unbalanced immune reactions are the cause or the consequence of the intestinal
dysbiosis observed in IBD patients remains to be elucidated.
The human gastrointestinal tract harbors a complex and dynamic community of
microbes, namely archaea, eukaryotes, viruses, and predominantly bacteria. This variety
of microorganisms constitutes the so-called gut microbiota, while the gut microbiome
encompasses these microorganisms along with their genes. The human genome consists
of about 23,000 genes, whereas the microbiome encodes over three million genes, which
replace many host functions, consequently influencing the host phenotype and health [9].
There is a great relationship between the human host and its gut microbiota. Gut
microbiome research has identified three primary functions of the intestinal microbiota:
(1) Nutrition and metabolism functions, as a result of the biochemical activity of the
microbiota, which include energy recovery in the form of short-chain fatty acids (SCFA),
vitamin production, and favorable effects on calcium and iron absorption in the colon;
(2) protective functions, preventing the invasion of infectious agents or overgrowth of
resident species with pathogenic potential; and (3) trophic effects on intestinal epithelial
proliferation and differentiation, affecting neuroendocrine pathways, and on immune
system development and modulation [10]. The gut microbiota is a component of the
gut barrier, a pivotal complex structure which acts as a frontier between the host and the
environment, thus regulating the interaction between the host and bacteria, and modulating
nutrient absorption [11]. Consequently, any alteration of the microbiota can lead to a
number of gastrointestinal disorders and metabolic diseases. Figure 1 summarizes gut
microbiome functions in healthy adults.
Figure 1. Gut microbiome functions in healthy adults. Adapted from Aziz et al. (2013) [10] and
Rowland et al. (2018) [12]. Abbreviations: SCFA, short-chain fatty acids; GALT, gut-associated
lymphoid tissue.
Advances in DNA sequencing technologies have significantly contributed to our
knowledge of the complexity of this ecosystem. The actual picture indicates that there is no
single healthy microbiome since microbiome characteristics are different for each individual.
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In general terms, microbial balance is needed in order to optimally support metabolic and
immune functions as well as prevent disease development. In a healthy gut, pathogenic
and symbiotic microbiota coexist without problems. However, any disturbance in that
balance leads to dysbiosis, thereby altering normal interactions between microorganisms
and the host. As a result, the host may become more susceptible to disease [13]. While the
disruption in the equilibrium of the intestinal milieu in IBD is widely accepted, alterations
involving biological mechanisms driving dysbiosis remain unknown and it is unclear
whether dysbiosis represents a cause or consequence of the disease.
In this review we will focus on how the development of microbiota and the immune
system during life contributes to establishing immunological tolerance. In addition, we
present IBD as a paradigm of how defects in this process can lead to disease.
2. Methods
Data were obtained from articles published in English belonging to journals indexed
in PubMed from inception to December 2020. Included search terms were related to
(1) immune system maturation, (2) gut microbiota establishment, (3) gut dysbiosis and
IBD, and (4) microbiota and modulation of immune system.
3. Microbiota and Intestinal Immune System Development
Immune system maturation and microbiota colonization are processes generally
considered to take place in parallel after birth. Before birth, the fetus develops an immature
immune system, whose innate immune cells (dendritic cells, monocytes, macrophages,
natural killer cells, innate lymphoid cells, neutrophils) are generated at different time-points
during gestation. These innate cells show low responsiveness to antigens [14] and reduced
pro-inflammatory cytokine production [15]. This “muted” immune system is probably
necessary to ensuring tolerance to antigens and antibodies transmitted from the mother to
the fetus, and also important to facilitating other physiological processes during in utero
development. Upon birth, adaptive immune cells (T and B lymphocytes) are mostly naïve,
although they also include relevant numbers of regulatory T cells (Treg). Besides, the
fetus and neonate’s immune response is skewed toward a Th2 phenotype, reinforcing the
tolerogenic behavior of the immune system [14,15]. It is noteworthy that the generation of
immune memory needs the contact with foreign antigens; however, since in utero the fetus
is only exposed to maternal antigens memory lymphocytes are scarce before birth. Likewise,
immunoglobulin M (IgM) is predominant in the neonate because the immunoglobulin
class-switch in B cells rarely takes place during gestation [15]. Besides, some secondary
lymphoid tissues (such as spleen, lymphoid nodes, and Peyer’s patches) are developed
during gestation, whereas others (cryptopatches and isolated lymphoid follicles) depend
on the stimulation of the immune system by an early microbial colonization, and therefore
are formed after birth [16].
Microbial colonization starts at birth, although it may occur even before, as some
bacterial species have been found in the placenta, the umbilical cord, and the amniotic fluid.
The composition of this initial microbiota is influenced by perinatal conditions (mode of
delivery, type of feeding or antibiotic usage), factors associated with the mother (diet, age
and metabolic status), the host genetics and the family’s lifestyle [17].
First colonizers are facultative anaerobes that promote an adequate environment for
strict anaerobes. Additionally, the newborn diet, consisting only of breast milk or infant
formulas, has great impact on the establishment of the infant’s early microbiota (for the
purposes of this review, we will focus on the effects of breast milk). Human breast milk main
components are proteins, lipids, oligosaccharides (HMO, human milk oligosaccharides)
and immune molecules, as well as some bacterial species (such as Bifidobacterium) that
might be another important microbial source for the infant’s gut [18,19]. Although the
human gut lacks enzymes to digest HMO, members of Bifidobacteria species can use them
as an energy source. Therefore, HMO composition influences the selection of microbial
species that are nurtured in the infants’ intestine; in addition HMO are also able to inhibit
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microbial adhesion to and invasion of the gut mucosa, offering an additional protection
against infections [20].
Bifidobacteria degrade HMO into monosaccharides and oligosaccharides that support
the growth of other microbes, leading to the establishment of the microbial community.
Consequently, the microbiota is distributed along the gastrointestinal tract depending on
factors such as acidity, oxygen tension, transit time, and nutrient absorption [21]. Thus,
microbes are less abundant in the stomach (where acidity compromises their survival) and
become progressively more abundant along the gastrointestinal tract until reaching their
highest amounts in the colon [22]. The assembly of these microbial communities within
the gastrointestinal tract during early life plays a critical role in immune, endocrine, and
metabolic host functions, among others [23].
Fermentation of HMO by Bifidobacteria also produces SCFA, which are an important
source of energy for enterocytes and are key signaling molecules for the maintenance of
gut health and immune tolerance. Additionally, HMO have been suggested to have anti-
inflammatory properties, which could be implicated in the development and maturation
of the intestinal immune system [20]. Moreover, they are able to modulate intestinal
epithelial cell responses, induce apoptosis, and promote a balanced Th1/Th2 cytokine
production [19].
Breast milk, as previously mentioned, also contains immune molecules and antimicro-
bial components, including anti-inflammatory molecules (such as interleukins [IL] 1, 6, 8
and 10; and transforming growth factors), molecules with the potential to mediate B cell
growth and differentiation, and modulators of pattern-recognition receptors (soluble TLR2
and 4, soluble CD14) that might help in the initial establishment of beneficial microbiota
in the neonate [18]. Moreover, human breast milk contains a large amount of maternal
immunoglobulin A (IgA), which is its most abundant immune molecule, together with
maternal immunoglobulin G (IgG). Altogether, these molecules will passively protect the
breast-fed baby against infections while his/her immune system is maturing [14,18].
Few months after birth, gradual introduction of solid food until weaning is completed
is accompanied by a change in gut microbiota composition. Milk-consuming bacteria such
as Bifidobacteria species become less abundant, while butyrate producers belonging to the
Bacteroidetes and Firmicutes phyla significantly increase. As a consequence, during early
infancy gut microbiota composition is less diverse and highly variable; however, around
2–5 years of age the composition, diversity and functional capabilities of gut microbiota
resemble those of adults [17].
Early gut colonizers are able to prime mucosal T cells, generating not only immune
memory but also promoting the development of T helper cells (Th1, Th2, Th17) and Treg.
Upon weaning, the mother’s passive protection fades, and the infant becomes more vul-
nerable to infections. Then, microbes, environmental antigens and vaccines contribute
to a gradual maturation of the immune system during infancy [14], generating immune
memory that lasts for decades. All of these interactions also promote immunoglobulin
isotype class-switch and the development of the immunoglobulin repertoire, conferring a
long-lasting humoral protection mediated by both plasma cells and memory B lympho-
cytes [14,15].
In adulthood, the microbiome is relatively stable, however is highly variable among
individuals and it is subject to perturbation by life events such as diet, medication, exposure
to pathogens, age, stress/anxiety, physical activity, tobacco use, or alcohol consumption;
then, it declines in old age [21]:
The normal human gut microbiota is primarily composed of two dominant bacterial
phyla, Firmicutes and Bacteroidetes, that represent more than 90% of the community,
and by other less abundant phyla including Proteobacteria, Actinobacteria, and Verru-
comicrobia [24]. Even though there is a common core, composed predominantly of the
aforementioned bacterial phyla, the composition and diversity of gut microbiota vary along
the gastrointestinal tract, showing a steady increase in the microbial concentration from
small numbers in the stomach to very high concentrations in the colon [13,25]. In addition,
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within the gut, there is also a difference in microbial populations between mucosal surfaces
and the lumen [26,27]. Microbes at the mucosal surface are in closer proximity to the
intestinal epithelium and may have a greater influence on the immune system, whereas
luminal/fecal microbes might be more essential for energy and metabolic interactions [26].
Microbiota composition changes in the elderly (over 65 years old), who present a
decrease in anaerobic bacteria such as Bifidobacterium spp. and an increase in Clostridium and
Proteobacteria [21]. Aging is also associated with the process of immunosenescence, which
is characterized by an aberrant immune response usually associated with inflammation.
This unbalanced immune reaction in the elderly may also impact the relation between host
and microbiota, altering microbiota diversity, as well as impairing the development of
tolerance to self-antigens, thereby leading to autoimmune disorders [14].
4. Gut Dysbiosis in Inflammatory Bowel Disease
4.1. Microbial Gut Dysbiosis
Dysbiosis refers to an imbalance in microbial species abundance, which is commonly
associated to impaired gut barrier function and inflammatory activity [28]. While some
microorganisms are considered essential regulators of the immune system, others can
trigger proinflammatory pathways and cause diseases. Major traits of dysbiosis are loss
of beneficial microbes, expansion of pathobionts, and loss of microbial diversity [13]. Gut
dysbiosis is linked to many diseases, including IBD [29], type 2 diabetes [30], cardiovas-
cular diseases [31], and neuropsychological conditions triggered through the “gut-brain
axis” [32]. Yet its role and dynamics in health and disease are poorly understood.
To date, numerous microbiome surveys have been conducted to identify the gut
microbiome profile in IBD, especially focusing on the differences between the profile of IBD
patients and that of healthy controls. Compelling studies in animal models and humans
have provided evidence of persistent imbalance on the gut microbiome in IBD [29,33–82].
However, it remains to be determined whether these changes in the microbiome are the
cause of IBD or rather the result of inflammation after IBD onset. Table 1 shows the cardinal
features consistently found in IBD dysbiosis.
Table 1. Main features consistently found in inflammatory bowel disease gut microbiome. Summa-
rized from [34–43,45–54,56–65,67–76,78–82].
Features Consistently Found in Inflammatory Bowel Disease Gut Microbiome
Decreased diversity
Reduced community stability
Decrease in the Firmicutes Phyla and increase of Bacteroidetes
Decrease in Clostridium XIVA and IV (Faecalibacterium, Lachnospiraceae, Clostridiumcocoides) and
increase in Proteobacteria (Enterobacteriaceae)
Decrease in Faecalibacterium prausnitzii and Roseburia hominis
Increase in Ruminococcus gnavus and adherent-invasive Escherichia coli
Increased fungal abundance, mainly Candida albicans
Increase of Caudovirales and eukaryotic viruses
Bacteriome and virome correlations
Current research on microbiome is mainly focused on bacteria, however the gastroin-
testinal tract is colonized by trillions of microorganisms that include bacteria, archaea,
fungi, and viruses. These non-bacterial microbial communities also play a vital role in host
health and disease [83–85]. It is well established that IBD is affected by several types of
microbial species, including fungi, archaea, bacteria, and viruses. Accordingly, deciphering
the function and composition of the human gut microbiome in the progression of chronic
inflammation in the intestine is crucial to further understand the pathogenic mechanisms
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of IBD. Table 2 shows the immune pathways that may be affected by microbial taxa altered
in IBD.
Table 2. Gut microbiome in inflammatory bowel disease and its associations with the immune system.
Depleted Immune Association
SCFA producing bacteria (F. prausnitzii, Roseburia, Eubacterium)
Produce SCFA playing a major role in modulation of
inflammation, regulation of immune responses, maintenance of
barrier integrity in the gut, enhanced expansion of Treg
population and skew of human dendritic cells to prime
IL-10-secreting T cells [86–88].
B. fragilis Produces lipid antigens controlling homeostatic iNKT cellproliferation and activation [89].
Bifidobacterium Inhibits intestinal inflammation by acting on Treg cells [90].
Mbb. smithii Weak association with proinflammatory mechanisms [91].
Enriched Immune association
E. coli (adherent invasive) Invades intestinal epithelial cells, replicates in macrophages andinduces granulomas [92].
Proteobacteria (Salmonella, Yersinia, Desulfovibrio, Helicobacter,
Vibrio)
Associated with a proinflammatory state as revealed by
quantification of common proinflammatory interleukins. The
inflamed gut appears to provide a favorable environment for
expansion of this phyla [93].
R. gnavus Secretes a complex glucorhamnan polysaccharide inducingTNFα secretion by dendritic cells [94].
Fusobacterium
Especially F. nucleatum, which is a well-recognized
proinflammatory bacterium [95] and it may secrete Outer
Membrane Vesicles (OMVs) that activate epithelial TLR4 to
drive inflammation [96].
C. albicans Interacts with mucosal innate immune cells through thepathways associated with Dectin-1 in macrophages [97].
Bacteriophages (Caudovirales and Microviridae)
May play a direct role in intestinal physiology or change the
bacterial microbiome through predator-prey relationships [76].
Enterobacteria are the main hosts of Microviridae [98].
Eukaryotic viruses
Infect host cells and may increase host susceptibility to IBD by
supporting a long-standing immune response through
inflammatory mediators, as well as by inducing alterations in
the composition of the commensal microbiota [99].
M. stastmanae Leads to substantial release of proinflammatory cytokines inmonocyte-derived dendritic cells [91].
Abbreviations: Short chain fatty acids (SCFA), invariant natural killer T (iNKT) cells, Toll-like receptor 4 (TLR4), Inflammatory bowel
disease (IBD).
In the next sections we will briefly summarize the gut dysbiosis associated to each of
the four aforementioned microbial communities.
4.2. Bacterial Dysbiosis
Bacterial gut microbiome data show that there is a disease-dependent reduction of
biodiversity and an imbalanced bacterial composition in the gut of IBD patients com-
pared to healthy controls. The gut dysbiosis profile is also different between IBD patients
undergoing different disease activities (flare or remission) [49,53,54,67,100–106].
The main feature in IBD gut dysbiosis is the decrease in beneficial bacteria. The
number of SCFA-producing bacteria such as Faecalibacterium prausnitzii, Roseburia, or Eu-
bacterium is reduced, which may lead to disease, since SCFA strengthens the intestinal
barrier and the immune system, thereby contributing to fight pathogens [86–88]. In the
Bacteroidetes phyla, Bacteroides fragilis, a bacterium that can induce Treg growth and expres-
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sion of cytokines with protective effects against colitis [89,107] has been consistently shown
to be decreased in IBD [46,80,108–110]. Depletion of Bifidobacterium, another beneficial
genus in the Actinobacteria phyla exerting important functions in gut homeostasis and
health [90,111], has been also reported in the gut of IBD patients [59,112–117]. However,
controversial results were found within this genus, as other authors also reported its in-
crease in IBD patients compared to controls [47,48,63,100]. A plausible explanation is the
effect of disease activity, as Bifidobacterium genus is significantly decreased in stool samples
of active CD and UC compared to the inactive state [105,118,119]. Nevertheless, further
research is needed to elucidate the role of this protective genus in IBD pathogenesis.
In parallel, a significant increase in some pathogens such as Proteobacteria (adherent-
invasive Escherichia coli, Pasteurellaceae), Firmicutes (Veillonellaceae and Ruminococcus gnavus),
and Fusobacterium species has been widely reported. Especially, the increase of the phylum
Proteobacteria, which is associated with a proinflammatory state [106] and includes multi-
ple genera considered potentially pathogenic such as Escherichia, Salmonella, Yersinia, Desul-
fovibrio, Helicobacter, or Vibrio, has been extensively reported in IBD patients [35,43,45–52,79].
The most recurring and contrasted finding is the increase of adherent-invasive E. coli in the
gut of IBD patients; this infectious agent is able to adhere to and cross the intestinal mucus
barrier, invading the gut epithelial layer. Moreover, this species is capable of surviving and
replicating in macrophages, leading to TNFα secretion and inflammation [92,120].
4.3. Fungal Dysbiosis
Fungi constitute approximately 0.1% of the total microbial community in the gut [24]
yet changes in gut mycobiota have been also reported in IBD patients. The innate immune
response against molecules in fungal cell walls is complex and incompletely character-
ized [84,121]. Fungi interact with host immune system via Toll-like receptors (TLR2 and
TLR4 predominantly), dectin-1 (CLEC7A), scavenger receptor family (CD5, CD36, and
SCARF1), and components of the complement system, which can be activated by fungal cell
wall glycoprotein components, such as beta-glucans, chitin, and mannans. Such interaction
leads to immune signaling via molecules such as CARD9, IL17, IL22, NF-κB, NFAT, and
ITAM containing receptors [84,97]. For example, dectin-1-deficient mice show increased
susceptibility to chemically induced colitis, probably due to a disturbed ability to mount
effective immune response against the commensal fungal community of the intestinal
microbiota [122].
Studies on changes in fungal diversity between IBD patients and controls have shown
controversial results. While in some cases fungal diversity was shown to be decreased in
UC patients [69,123], in others diversity and richness was reduced in CD [70,72,73,124],
and even showed no difference between IBD patients and control groups [68]. An in-
crease in fungal load, especially in Candida albicans [68–73], is the most solid conclusion
across studies.
Literature has shown interkingdom correlations among Candida tropicalis, E. coli, and
Serratia marcescens in CD patients [124]. This network between bacteria and fungi opens a
new avenue for research in gut microbiome dysbiosis and may increase our understanding
of the underlying mechanisms and role of the gut mycobiota in the development of IBD.
4.4. Viral Dysbiosis
The human gut virome includes a diverse collection of viruses directly impacting on
human health, including physiological members of the healthy gut microbiota, mostly
bacteriophages and eukaryotic viruses [83]. DNA sequencing technology showed that bac-
teriophages represent the most abundant members of the human gut virome [125]. Viruses
can provide bacteria with genes encoding for different functions, and such interkingdom
interactions can confer genetic variations to the host microbiome that may contribute
to establishing specific phenotypes. This underlines the importance of gut virome in
genotype–phenotype studies and suggests a crucial role of viruses in the host [98].
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In stool samples, Norman et al. described the enteric virome and its specific alteration
in IBD. These researchers showed that Caudovirales and Microviridae are the most abundant
families of bacteriophages in the enteric virome. They revealed that IBD is associated with
significant expansion of Caudovirales [76]. In gut biopsies, phage populations are increased
and significantly different in patients with IBD when compared to controls [74,75].
Pérez-Brocal et al. conducted a linear discriminant analysis effect size (LEfSe) with
differential viral discriminant features showing statistical significance for several species in
feces from patients with CD compared to healthy controls; especially, increased numbers
of overrepresented viruses were observed in feces from patients with CD [126]. They also
found that gut virome modification in newly diagnosed IBD patients could be associated
with inflammation and linked to bacterial dysbiosis. This observation is in accordance
with other investigations in which an inverse correlation was observed between IBD-
associated changes in the virome and bacterial microbiome, suggesting a possible model
where changes in the gut virome may affect bacterial dysbiosis and/or intestinal inflamma-
tion [75,76]. Besides, certain eukaryotic viruses might trigger intestinal inflammation and
contribute to IBD pathogenesis [99,127,128].
4.5. Archaeal Dysbiosis
Prokaryotes forming the domain of Archaea can also colonize distinct niches in
the human body, including the gut. Methane-producing archaea (methanogens) play
an important role in digestion, improving polysaccharide fermentation by preventing
accumulation of acids, reaction end products, and hydrogen gas [129].
Some studies associated an altered proportion of archaea with IBD. Lecours et al. [130]
showed that the abundance of Methanosphaera stastmanae in fecal samples was significantly
higher in IBD patients than in healthy subjects. Interestingly, only IBD patients developed
a significant anti-Msp. stadtmanae IgG response, indicating that the composition of archaeal
microbiome appears to be an important determinant of the presence or absence of autoim-
munity. Another study demonstrated an inverse association between Methanobrevibacter
smithii load and susceptibility to IBD, which could be extended to IBD patients in remission
as Mbb.smithii load was found to be markedly higher among healthy subjects in comparison
to IBD patients [131]. Controversial results were found by Chehoud et al. [132] who showed
no alterations in the archaeal colonization of the gut associated with IBD and found that
archaea seemed to be rare in pediatric samples compared to those from adults.
5. The “Hygiene Hypothesis”, Dysbiosis and Inflammatory Bowel Disease
The “hygiene hypothesis” suggests that a lack of early childhood exposure to symbi-
otic microorganisms and helminthic parasites affects immune development increasing the
susceptibility to immune-mediated diseases later in life. Weinstock et al. [133] suggested
that urbanization and environmental changes toward a more hygienic status diminished
the prevalence of helminth colonization in the host leading to a higher incidence of IBD.
This hypothesis agrees with findings of Deepshik et al. [134], who demonstrated that
helminth infection protects mice deficient in the CD susceptibility gene NOD2 from intesti-
nal alterations by inhibiting colonization by inflammatory Bacteroides species. In murine
and human studies, they demonstrated that infections with gastrointestinal helminths can
protect against IBD by causing immune responses that alter the balance of commensal and
pathogenic bacteria in the gut. Another parasites, such as Blastocystis, were significantly
less frequent in UC patients as compared to healthy controls [135], which reinforces the
“hygiene hypothesis.”
Helminths and other parasites are not assessed in microbiome studies as they do not
fall in the “microorganisms category,” however its inclusion may improve the understand-
ing of the immune mechanisms underlying IBD pathogenesis.
An interesting aspect of the “hygiene hypothesis” is the fact that the proposed action
of symbiotic microorganisms and parasites on the immune system takes place during
infancy, which is the critical time-period when a healthy symbiotic relationship is estab-
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lished between the host and the intestinal microbiota. Therefore, it is a matter of debate
whether there might be a “window of opportunity” [136] to restore any alteration in the
microbial colonization and the subsequent immune imprinting, in order to prevent chronic
inflammatory diseases such as IBD (nicely reviewed by Nabhani and Eberl (2020) [136]).
6. Conclusions
Correct interplay between gut microbiota and the host is essential for human health.
Microbial balance is pivotal for host metabolic and immune functions as well as to prevent
disease development. Disturbance in that balance generates dysbiosis making the host
susceptible to certain diseases. Gut microbiota stimulates the immune system, and altered
composition of this microbiota in early life can lead to an inadequately trained immune
system that can overreact to commensal microbes and lead to inflammatory diseases.
Recent research has provided striking findings supporting that the gut microbiome
plays an important function in the etiopathogenesis of IBD. Most of the available evidence
comes from studies on bacteria, whereas data on the role of fungi, viruses, or archaea
are limited. Modifications in specific microbial species, affecting both their diversity and
stability, have been identified in IBD.
These microbial alterations of the gut may cause dysregulated mucosal immune
responses leading to the onset of IBD, as many of the altered taxa have a direct impact
on certain immune pathways, specially favoring a proinflammatory environment. The
functional significance of these changes and their pathogenic role remain to be discovered.
The complex interplay between the microbiota, the intestinal mucosa, and the immune
system highlights the importance of a comprehensive approach to unravel the mechanisms
underlying intestinal dysbiosis.
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